S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

NovoCure Stock Forecast, Price & News

-11.39 (-6.37 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $167.55
50-Day Range
MA: $161.08
52-Week Range
Now: $167.55
Volume923,218 shs
Average Volume787,799 shs
Market Capitalization$17.06 billion
P/E Ratio881.89
Dividend YieldN/A
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
NovoCure logo


Overall MarketRank

1.46 out of 5 stars

Medical Sector

408th out of 1,556 stocks

Surgical & Medical Instruments Industry

45th out of 137 stocks

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:NVCR



Sales & Book Value

Annual Sales$351.32 million
Book Value$2.20 per share


Net Income$-7,230,000.00


Market Cap$17.06 billion
Next Earnings Date2/25/2021 (Confirmed)
-11.39 (-6.37 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

NovoCure (NASDAQ:NVCR) Frequently Asked Questions

How has NovoCure's stock been impacted by Coronavirus (COVID-19)?

NovoCure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVCR shares have increased by 148.7% and is now trading at $167.55.
View which stocks have been most impacted by COVID-19

Is NovoCure a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NovoCure stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares.
View analyst ratings for NovoCure
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than NovoCure?

Wall Street analysts have given NovoCure a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NovoCure wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is NovoCure's next earnings date?

NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for NovoCure

How can I listen to NovoCure's earnings call?

NovoCure will be holding an earnings conference call on Thursday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) released its quarterly earnings results on Thursday, October, 29th. The medical equipment provider reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. The medical equipment provider had revenue of $132.70 million for the quarter, compared to analysts' expectations of $120.02 million. NovoCure had a return on equity of 7.40% and a net margin of 4.26%. The company's revenue was up 44.1% on a year-over-year basis. During the same quarter last year, the business earned $0.02 earnings per share.
View NovoCure's earnings history

What guidance has NovoCure issued on next quarter's earnings?

NovoCure issued an update on its FY 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $494.4-494.4 million, compared to the consensus revenue estimate of $482.29 million.

What price target have analysts set for NVCR?

9 analysts have issued 1 year price targets for NovoCure's stock. Their forecasts range from $58.00 to $159.00. On average, they anticipate NovoCure's stock price to reach $112.38 in the next twelve months. This suggests that the stock has a possible downside of 32.9%.
View analysts' price targets for NovoCure
or view Wall Street analyst' top-rated stocks.

Are investors shorting NovoCure?

NovoCure saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 5,880,000 shares, an increase of 17.8% from the December 15th total of 4,990,000 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is presently 5.0 days. Approximately 6.8% of the company's stock are short sold.
View NovoCure's Short Interest

Who are some of NovoCure's key competitors?

What other stocks do shareholders of NovoCure own?

Who are NovoCure's key executives?

NovoCure's management team includes the following people:
  • Mr. William F. Doyle, Exec. Chairman (Age 58, Pay $1.66M)
  • Mr. Asaf Danziger, Pres, CEO & Director (Age 54, Pay $1.69M)
  • Mr. Wilhelmus C. M. Groenhuysen, Chief Operating Officer (Age 62, Pay $1.02M)
  • Mr. Pritesh Shah, Chief Commercial Officer (Age 42, Pay $725.6k)
  • Prof. Yoram Palti, Founder & CTO (Age 82)
  • Ms. Ashley Cordova, CFO & VP of Investor Relations
  • Mr. Todd C. Longsworth, Gen. Counsel (Age 45)
  • Dr. Ely Benaim, Chief Medical Officer (Age 59)
  • Mr. Uri Weinberg M.D., Ph.D., Chief Science Officer
  • Mr. Frank Leonard, Chief Devel. Officer

What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by a number of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.10%), Brookstone Capital Management (0.01%), Sheets Smith Wealth Management (0.00%), Kovack Advisors Inc. (0.00%), Redpoint Investment Management Pty Ltd (0.00%) and XR Securities LLC (0.00%). Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for NovoCure

Which institutional investors are selling NovoCure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Sowell Financial Services LLC, and Scout Investments Inc.. Company insiders that have sold NovoCure company stock in the last year include Asaf Danziger, Ashley Cordova, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for NovoCure
or view top insider-selling stocks.

Which institutional investors are buying NovoCure stock?

NVCR stock was acquired by a variety of institutional investors in the last quarter, including Brookstone Capital Management, Sheets Smith Wealth Management, Kovack Advisors Inc., Redpoint Investment Management Pty Ltd, XR Securities LLC, and Diversified Trust Co.
View insider buying and selling activity for NovoCure
or or view top insider-buying stocks.

How do I buy shares of NovoCure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $167.55.

How big of a company is NovoCure?

NovoCure has a market capitalization of $17.06 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. NovoCure employs 782 workers across the globe.

What is NovoCure's official website?

The official website for NovoCure is www.novocure.com.

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.